On April 1, 2026, BioXcel Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug Application (sNDA) for IGALMI, a treatment for acute agitation associated with bipolar disorders or schizophrenia in outpatient settings. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of November 14, 2026. This acceptance is a significant milestone for BioXcel as it seeks to expand the indications for IGALMI, which has already shown promise in treating agitation in patients. The company believes that this development could enhance its market position and provide additional revenue streams, particularly in the growing mental health treatment market. The acceptance of the sNDA indicates the FDA's recognition of the potential benefits of IGALMI in managing acute agitation, which is a critical aspect of care for patients with bipolar disorder and schizophrenia. BioXcel's management expressed optimism about the upcoming review and the potential for IGALMI to address unmet needs in this patient population. The company is committed to advancing its clinical programs and is focused on delivering innovative solutions to improve patient outcomes. Investors and stakeholders are encouraged to monitor the progress leading up to the PDUFA date, as positive outcomes could significantly impact BioXcel's stock performance and overall market valuation.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.